Relationship between gingival hyperplasia and class II histocompatibility antigens in renal transplant recipients

Nephron

Volumn 84, Issue 1, 2000, Pages 29-31

  Türkmen, Aydin ^b   Ak, Gülsüm ^a   Furuncuoǧlu, Yavuz ^b   Akar, Uǧur ^b   Seyhun, Yalçin ^b   Türk, Süleyman ^b   Çarin, Mahmut ^b   Sukru Sever M ^b  

^a School of Dentistry   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Ciclosporin A; Gingival hyperplasia; Major histocompatibility complex antigens; Nifedipine

Indexed keywords

AMLODIPINE; AZATHIOPRINE; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN A; DIHYDROPYRIDINE; DILTIAZEM; HLA DR1 ANTIGEN; HLA DR2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NIFEDIPINE; PREDNISONE; VERAPAMIL;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; GINGIVA HYPERPLASIA; HISTOCOMPATIBILITY COMPLEX; HUMAN; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0033980014     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: 10.1159/000045535     Document Type: Article

References (12)

1. Daley TD, Wysocki GP, Day C: Clinical and pharmacologic correlations in cyclosporine induced gingival hyperplasia. Oral Surg Oral Med Oral Pathol 1986;62:417-421.
2. King GN, Fullinfaw R, Higgins TJ, Walker RG, Francis DMA, Wiesenfeld D: Gingival hyperplasia in renal allograft recipients receiving cyclosporine A and calcium antagonists. J Clin Periodontol 1993;20:286-293.
3. Seymour RA, Smith DG, Rogers SR: The comparative effects of azathioprine and cyclosporine on some gingival health parameters of renal transplant patients: A longitudinal study. J Clin Periodontol 1987;14:610-613.
4. Thomason JM, Seymour RA, Ellis J: The periodontal problems and management of the renal transplant patient. Ren Fail 1994;16:731-745.
5. Margiotta V, Pizzo I, Pizzo G, Barbara A: Cyclosporine and nifedipine induced gingival overgrowth in renal transplant recipients: Correlation with periodontal and pharmacological parameters and HLA antigens. J Oral Pathol Med 1996;25:128.
6. Lucas RM, Howell LP, Wall BA: Nifedipine induced gingival hyperplasia. J Periodontol 1985;56:211.
7. Morgano A, Pierri I, Stagnaro R. Setti M, Puppo F, Indiveri F: Decreased lymphocyte blastogenesis, IL-2 production and NK activity following nifedipine administration to healthy humans. Eur J Clin Pharmacol 1990;39:545-550.
8. Padberg WM, Bodewig C, Schäfer H, Muhrer KH, Schwemmle K: Synergistic immunosuppressive effect of low-dose cyclosporine A and the calcium antagonist nifedipine mediated by the generation of suppressor cells. Transplant Proc 1990;22:2337.
9. Solovera JJ, Alvarez-Mon M, Casas J, Carballido J, Durantez A: Inhibition of human natural killer (NK) activity by calcium channel modulators and a calmodulin antagonist. J Immunol 1987;139:876-880.
10. Zlabinger GJ, Kudlacek S, Pohanka E, Franz M, Hamilton G, Rosenmayr A, Kovarik J: Evidence that sensitivity to cyclosporine is influenced by the HLA-DR phenotype of kidney graft recipients. Transplantation 1992;53:758-762.
11. Pernu HE, Knuuttila MLE, Huttunen KRH, Tiilikainen ASK: Drug-induced gingival overgrowth and class II major histocompatibility antigens. Transplantation 1994;57:1811-1823.
12. Cebeci I, Kantarci A, Firatli E, Aygün S, Tanyeri H, Aydin AE, Çarin M, Güç Ü. Tuncer Ö: Evaluation of the frequency of HLA determinants in patients with gingival overgrowth induced by cyclosporine A. J Clin Periodontol 1996;23:737-742.